Company Overview#
Botanix Pharmaceuticals Ltd (ASX:BOT) has released its financial results for the third quarter of 2026, marking a pivotal shift from being a development-stage company to generating revenue. The company reported strong financial performance, highlighted by record prescription shipments and a solid cash position, although its stock price fell by 5% after the announcement.
Key Financial Highlights#
Botanix's financial results indicate a trailing 12-month gross revenue of AUD 120 million. In Q3 2026, the company shipped 26,684 prescriptions, showing its ability to effectively meet market demand. Additionally, the gross-to-net yield improved from 16% to 19% by the end of the quarter, indicating better profitability from sales. The company's cash position also strengthened, with a pro forma cash balance of AUD 50.8 million.
Market Reaction#
Despite the positive revenue growth, Botanix's stock price declined by 5% following the earnings announcement. The stock is currently trading at AUD 0.03, just above its 52-week low of AUD 0.028. Over the past year, the stock has seen a significant decline of 93%. Analysts suggest that the stock may be undervalued, presenting potential opportunities for investors who can overlook short-term challenges.
Future Outlook#
Looking ahead, Botanix expects to continue its upward trajectory in gross-to-net revenue in Q4 2026, driven by the transition of high-deductible plan units to fully reimbursed units. The company projects an earnings per share (EPS) of -0.02 USD for FY2026 and -0.01 USD for FY2027, with revenue forecasts of USD 27.71 million and USD 56.43 million for FY2026 and FY2027, respectively. CEO of Botanix Pharmaceuticals emphasized the importance of their transition to a revenue-generating company, noting the strong demand for their flagship product, Sofdra.